Next-generation CAR T cell therapies for glioblastoma-Reference-Cited by-同舟云学术

Next-generation CAR T cell therapies for glioblastoma

Published:2024-08-28 Issue:762 Volume:16 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Bernstock Joshua D.¹²³^ORCID,Gerstl Jakob V. E.¹^ORCID,Valdés Pablo A.⁴^ORCID,Friedman Gregory K.⁵^ORCID,Chiocca E.¹^ORCID

Affiliation:

1. Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

2. Department of Neurosurgery, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA.

3. David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

4. Department of Neurosurgery, University of Texas Medical Branch, Galveston, TX 77555, USA.

5. Division of Pediatrics, Neuro-Oncology Section, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Abstract

Interim results from two phase 1 trials demonstrate progress in the use of chimeric antigen receptor (CAR) T cell therapy for recurrent glioblastoma (GBM).

Publisher

American Association for the Advancement of Science (AAAS)

Link

https://www.science.org/doi/pdf/10.1126/scitranslmed.adp2660

Reference10 articles.

1. Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results

2. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma

3. FDA approves first CAR T therapy;Mullard A.;Nat. Rev. Drug Discov.,2017

4. Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial

5. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas